



COSENTYX (secukinumab)

### **Instructions**

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

# Part A - Patient Patient Information

Patient information						
First Name:			Last Name:			
Insurance Carrier Name/Number:						
Group Number:			Client ID:			
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent			
Language: Eng	ilish  French		Gender: Male Female			
Address:						
City:		Province:		Postal Code:		
Email address:						
Telephone (home):		Telephone (cell):		Telephone (work):		
Please check any box that applies to the patient:  The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed.  The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.						
Coordination of benefits						
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.					
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A  What is the coverage decision of the drug? Approved Denied *Attach decision letter*					





COSENTYX (secukinumab)

### **Authorization**

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





COSENTYX (secukinumab)

## Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

COSENTYX (secukinumab)		New re	☐ New request ☐ Renewal request*		
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration	
Site of drug administra	l tion:				
Home Phys	sician's office/Private (	Clinic Private Clinic (within Hos	pital - no public or go	vernment funding)	
Hospital (inpatient)	Hospital (outp	agtiont)			
Name of the hospital o	r private clinic:				
Address:					
daress.					
City: Provi		rovince:	Postal code:		
* Please submit prop	f of prior coverage if av	/ailahle			
i icase subitite proo	i oi piloi coverage ii av	ranabic			
Tiedde dddiine proo	r or prior coverage if av	ranabic			
·	,	ranasic			
ECTION 2 – ELIGIB	,				
ECTION 2 - ELIGIB  1. Please indicate if	BILITY CRITERIA				
ECTION 2 - ELIGIB  1. Please indicate if	SILITY CRITERIA the patient satisfies the	e below criteria:			
1. Please indicate if the Plaque Psoriasis  For the treatment.	the patient satisfies the	e below criteria: vere plaque psoriasis, AND			
ECTION 2 - ELIGIB  1. Please indicate if the second	the patient satisfies the nent of moderate to seven 6 years of age or older	e below criteria: vere plaque psoriasis, AND		f the archioust's force	
Please indicate if the Plaque Psoriasis  For the treatm  The patient is  The patient has	the patient satisfies the nent of moderate to seven 6 years of age or older	e below criteria: vere plaque psoriasis, AND	nere is involvement of	f the patient's face,	
Please indicate if the Plaque Psoriasis  For the treatment is the patient is hands, feet or	the patient satisfies the nent of moderate to seven 6 years of age or older as an affected body sure genital region, AND	e below criteria: vere plaque psoriasis, AND		f the patient's face,	
Plaque Psoriasis  For the treatm The patient is hands, feet or	the patient satisfies the nent of moderate to several second of the seco	e below criteria: vere plaque psoriasis, AND r, AND rface area (BSA) of 10% or greater, or th	eater, AND	·	
Please indicate if the Plaque Psoriasis  For the treatment is the patient is the patient has been dead on the patient has inaccessible, and the patient has inaccessible and the patient has inac	the patient satisfies the nent of moderate to seven as an affected body surgenital region, AND as a Psoriasis Area and as had an inadequate rAND	e below criteria:  vere plaque psoriasis, AND  r, AND  rface area (BSA) of 10% or greater, or the second of 10 or greater, and the s	eater, AND nce to phototherapy,	unless it is	
Please indicate if the Plaque Psoriasis  For the treatment is the patient is the patient has been dead on the patient has inaccessible, and the patient has inaccessible and the patient has inac	the patient satisfies the nent of moderate to seven as an affected body sure genital region, AND as a Psoriasis Area and as had an inadequate respondent as ha	e below criteria:  vere plaque psoriasis, AND  r, AND  rface area (BSA) of 10% or greater, or the second of 10 or greater, and the s	eater, AND nce to phototherapy,	unless it is	
ECTION 2 - ELIGIB  1. Please indicate if the second	the patient satisfies the nent of moderate to seven as an affected body sure genital region, AND as a Psoriasis Area and as had an inadequate respondent as ha	e below criteria:  vere plaque psoriasis, AND  r, AND  rface area (BSA) of 10% or greater, or the second of 10 or greater, and the s	eater, AND nce to phototherapy,	unless it is	
Please indicate if the Plaque Psoriasis  For the treatment is the patient is the patient had hands, feet or the patient had inaccessible, and to another bid to provide the provided Psoriatic Arthritis	the patient satisfies the nent of moderate to seven as an affected body sure genital region, AND as a Psoriasis Area and as had an inadequate respondent as ha	e below criteria:  vere plaque psoriasis, AND  r, AND  rface area (BSA) of 10% or greater, or the severity Index (PASI) score of 10 or greaters or has a documented intolerate response or has a documented intolerater.	eater, AND nce to phototherapy,	unless it is	





COSENTYX (secukinumab)

Ankylosing Spondylitis							
For the treatment of ankylosing spondylitis in an adult, AND							
The patient has a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 4 or greater on a 10-point scale, AND							
inflammatory drugs (NSAIDs) for a minimum of 2 weeks	The patient has had an inadequate response or has a documented intolerance to at least 2 non-steroidal anti- inflammatory drugs (NSAIDs) for a minimum of 2 weeks each, or to at least 2 disease modifying anti-rheumatic drugs (DMARDs) for a minimum of 3 months, or to another biologic response modifier						
Non-Radiographic Axial Spondyloarthritis							
For the treatment of non-radiographic axial spondyloarthritis in an adult, AND							
The patient has objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), AND							
The patient has had an inadequate response or has a documented intolerance to at least 2 non-steroidal anti- inflammatory drugs (NSAIDs) for a minimum of 2 weeks each, or to another biologic response modifier							
Hidradenitis Suppurativa							
For the treatment of hidradenitis suppurativa in an adult, AND							
The patient has had an inadequate response or has a d	The patient has had an inadequate response or has a documented intolerance to systemic antibiotics, AND						
The patient has had an inadequate response or has a documented intolerance to a tumour necrosis factor (TNF) inhibitor (e.g. adalimumab)							
OB							
OR  None of the above criteria applies.							
Relevant additional information:							
SECTION 3 - PRESCRIBER INFORMATION							
Physician's Name:							
Address:							
Tel:	Fax:						
License No.:	Specialty:						
Physician Signature:	Date:						





COSENTYX (secukinumab)

#### SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at <a href="https://www.sunlife.ca/privacy">www.sunlife.ca/privacy</a> or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET

### **SECTION 5 - CONTACT US**

You can submit **all** pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of Canada Attention: Claims Dept. PO Box 2010 STN Waterloo

Waterloo, ON N2J 0A6